SOURCE: Ablynx

February 22, 2010 12:25 ET

ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2009 WITH WEBCAST

GHENT, BELGIUM--(Marketwire - February 22, 2010) - Ablynx [Euronext Brussels: ABLX] plans to announce its full year results for 2009 on 25 February 2009 after market closure.

Dr Edwin Moses, CEO and Chairman of Ablynx, will host a conference call webcast during which the full year results for 2009 will be presented, followed by a Q&A session. This event will be held on Friday, 26 February 2009 at 4.00 p.m. CET.

The conference call will be webcast live and can be accessed through the home page of the Ablynx website (www.ablynx.com). Shortly thereafter, a replay version of the webcast will be accessible on our website under Investor Relations, Newsroom, Events and Presentations: http://www.ablynx.com/investorrelations/english/newsroom_eventsandpresentations.php.

- ends -

About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 230 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development. So far, Nanobodies have been successfully generated against more than 190 different protein targets including several complex targets such as chemokines, GPCRs, ion channels and viruses, which are typically very difficult to approach with conventional monoclonal antibodies. Efficacy data have been obtained in 28 in vivo models for Nanobodies against a range of different targets.

Ablynx has an extensive patent position in the field of Nanobodies for healthcare applications. It has exclusive and worldwide rights to more than 130 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.

Ablynx has ongoing research collaborations and significant partnerships with several major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer (previously Wyeth Pharmaceuticals). Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies through these collaborations as well as through its own internal discovery programmes.

[HUG#1387136]

Complete version of the press release: http://hugin.info/137912/R/1387136/345518.pdf

Contact Information

  • For more information, please contact:

    College Hill Life Sciences - for International media enquiries:
    Sue Charles, Justine Lamond
    t: +44 (0)20 7866 7857
    f: +44 (0)20 7866 7900
    e: Email Contact

    Ablynx:
    Dr Edwin Moses
    Chairman and CEO
    t: +32 (0)9 262 00 07
    m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
    e: Email Contact

    Eva-Lotta Allan
    Chief Business Officer
    t: +32 (0)9 262 00 75
    m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
    e: Email Contact